HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 07-21-2006, 12:06 PM   #2
heblaj01
Senior Member
 
Join Date: Apr 2006
Posts: 543
Deoxypyridinoline as a early marker for bone metatases

In 2003 researchers in Taiwan published the results of their study of urine deoxypyridinoline tests for detecting & monitoring metastatic bone lesions as shown in abstract below.
In the full text of their paper where various ranges of deoxypyridinoline levels are provided with their significance, they claim that the test can detect bone metastases 3 to 6 months before any other marker (as of 2003).
If this test is not surpassed by better more recent markers it might still be an easy non invasive & relatively inexpensive diagnostic tool.

http://www.annclinlabsci.org/cgi/con...stract/33/1/55

Diagnostic Value of Urine Deoxypyridinoline for Detecting Bone Metastases in Breast Cancer Patients

Hou MF, Lin SB, Yuan SS, Tsai LY, Tsai SM, Hsieh JS, Huang TJ.

Department of Surgery, Obstetrics and Gynecology, Kaohsiung Medical University, Taiwan, Republic of China.

Deoxypyridinoline (Dpd), a crosslink product of collagen molecules found in bone and excreted in urine during bone degradation, has been described as a marker of bone turnover in metastatic breast cancer. In this study, the urine deoxypyridinoline/creatinine (Dpd/Cre) ratio was determined by enzyme immunoassay in urine samples from 116 women with breast cancer. Bone metastases were confirmed by x-ray or CT scan, with follow-up > 6 mo. The urine Dpd/Cre ratio was significantly higher in patients with bone metastasis, compared to those without bone metastasis (p < 0.05). In patients with bone metastasis, ratios of urine Dpd/Cre were higher in those with multiple lesions, compared to those with a solitary lesion, and the values also reflected therapeutic response (p < 0.05). Serial monitoring of urine Dpd/Cre revealed that an elevation was correlated with disease progression. Patients with stable bone disease under effective therapy had significant diminution of the urine Dpd/Cre ratios, compared to those with progression of bone disease (p < 0.05). In conclusion, the urine Dpd/Cre ratio may be a useful marker for detecting bone metastases and evaluating their response to therapy

Last edited by heblaj01; 07-21-2006 at 12:08 PM.. Reason: To correct inflated character size. 2nd try
heblaj01 is offline   Reply With Quote
 

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:44 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter